IceCure Medical Ltd. (ICCM)

NASDAQ: ICCM · IEX Real-Time Price · USD
1.72
+0.06 (3.61%)
Jul 5, 2022 11:29 AM EDT - Market open

Company Description

IceCure Medical is a commercial stage medical device company focusing on the research, development and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors.

In the United States our products are approved as a “single family” known as the “IceCure Family,” which includes the IceSense3, ProSense, and MultiSense (which has not been commercialized) cryoablation systems.

Cryoablation is the process by which benign and malignant tumors are ablated (destroyed) through freezing such tumors while in a patient’s body. Our proprietary cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications.

In our continued efforts aimed at improving our core technology, we are currently focusing on developing our next generation MultiSense system, which we intend to commercialize subject to regulatory approvals.

We are also in the process of developing our next generation single probe system. While these next generation systems are still in various research and development stages, we expect them to be more efficient and user friendly.

IceCure Medical Ltd.
Country Israel
Founded 2006
Industry Medical Devices
Sector Health Care
Employees 48
CEO Eyal Shamir

Contact Details

Address:
7 Ha’Eshel St., PO Box 3163
Caesarea 3079504
Israel
Phone 972 4 623 0333
Website icecure-medical.com

Stock Details

Ticker Symbol ICCM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1584371
ISIN Number IL0011224156

Key Executives

Name Position
Eyal Shamir Chief Executive Officer and Director
Ronen Tsimerman CPA Chief Financial Officer and Chief Operating Officer
Tlalit Bussi Tel-Tzure Vice President of Business Development and Global Marketing
Merav Nir Dotan Vice President of Human Resources
Naum Muchnik Vice President of Research, Development and Engineering
Shay Levav Vice President of Regulatory and Quality Assurance and Clinical Applications

Latest SEC Filings

Date Type Title
Jun 13, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Jun 9, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Jun 9, 2022 EFFECT Notice of Effectiveness
Jun 3, 2022 POS AM Post-Effective amendments for registration statement
May 18, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Apr 29, 2022 S-8 Securities to be offered to employees in employee benefit plans
Apr 5, 2022 EFFECT Notice of Effectiveness
Apr 4, 2022 POS AM Post-Effective amendments for registration statement
Apr 1, 2022 POS AM Post-Effective amendments for registration statement
Apr 1, 2022 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]